Skip to main content
Premium Trial:

Request an Annual Quote

Altana Acquires 8.3 Percent Stake in GPC Biotech

NEW YORK, Nov. 1 – German pharmaceutical company Altana has agreed to make an equity investment of 34.2 million euros ($31.1 million) in GPC Biotech, GPC said Thursday.

GPC of Munich said it would issue 1.69 million of its shares to Altana at 20.25 euros a share. Following the transaction, Altana will hold an 8.3 percent stake in GPC, making it the second largest shareholder in the company.

"GPC Biotech has proved itself in a reliable and competent partnership which builds the foundation for our entrance as strategic investor," Hans-Joachim Lohrisch, member of the managing board of Altana, said in a statement.

Since 1998, GPC and Altana’s pharmaceutical division, Byk Gulden, have collaborated to identify targets and validate research on new drug candidates. 

GPC Biotech uses proprietary genomic and proteomic technologies to identify targets and to validate potential therapeutics for cancer, infectious diseases, and immunology. The companies other partners include Aventis, Boehringer Ingelheim, Cell Genesys, and MorphoSys. The company has subsidiaries in Waltham, Mass., and Princeton, NJ.

Altana’s pharmaceutical group Byk Gulden is focused on developing new therapeutics and diagnostics.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.